ORBITA-CTO: Chronic total occlusion PCI in stable angina

8 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Kalaivani Mahadevan interviews Sarosh Khan and John Davies about the ORBITA-CTO trial: a first-ever randomised, double-blind, placebo-controlled trial evaluating CTO PCI in stable angina patients.
The investigators discuss the trial design, its highly rigorous blinding methodology, and the key findings showing that CTO PCI significantly reduces angina frequency and improves patient symptoms beyond placebo. They also explore the clinical implications, patient selection criteria, and remaining questions that will shape future research and decision-making in complex coronary interventions.

More updates on a selection of major LBTs of interest in interventional cardiology presented at the American College of Cardiology 2026 Scientific Sessions #ACC26 :
https://www.pcronline.com/News/Congress-coverages/ACC/2026/PCR-ACC-Scientific-Sessions
Categoria
Cardiology
Commenta per primo questo video.

Prossimo